IQ-AI Limited

Equities

IQAI

JE00BD4H0R42

Healthcare Facilities & Services

Delayed London S.E. Other stock markets 01:54:38 17/05/2024 pm IST			5-day change	1st Jan Change
1.5 ^GBX	+11.11%		-9.09%	-68.09%

10/05	IQ-AI subsidiary gets rare paediatric disease designation FDA	AN
10/05	IQ-AI's Imaging Biometrics Obtains Rare Pediatric Disease Designation for Lead Drug Candidate	MT

IQ-AI Limited shares latest progress from Phase I glioblastoma clinical trial

July 19, 2023 at 10:35 pm IST

(via NewsDirect)

Dr Jennifer Connelly, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Proactive's Natalie Stoberman to discuss the latest updates from its treatment for recurring glioblastoma patients.

IQ-AI Ltd, the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively.

Contact Details

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com

Latest news about IQ-AI Limited

IQ-AI subsidiary gets rare paediatric disease designation FDA	10/05	AN
IQ-AI's Imaging Biometrics Obtains Rare Pediatric Disease Designation for Lead Drug Candidate	10/05	MT
EARNINGS AND TRADING: Trident Royalties swings to profit	02/05	AN
IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024	29/04	CI
IQ-AI Limited Reports Earnings Results for the Full Year Ended December 31, 2023	29/04	CI
IQ-AI's Broker Exercises Option to Buy Shares in Placing	26/02	MT
IQ-AI Plans Share Placing to Advance Oral Anti-tumor Agent Development	22/02	MT
IQ-AI shares sink on discounted placing fundraise	22/02	AN
IQ-AI Unit to Revise, Resubmit Pediatric Rare Disease Designation Application After US FDA Feedback	09/02	MT
IQ-AI subsidiary asked by FDA to resubmit and modify application	09/02	AN
IQ-AI Unit Secures Grant for Brain Tumor Pill Access Program	02/02	MT
IQ-AI celebrates USD100,000 grant for subsidiary	02/02	AN
IQ-AI falls after subsidiary notes launch of treatment access scheme	10/01	AN
IQ-AI's Imaging Biometrics Plans Expanded Access Program for Brain Tumor Treatment	10/01	MT
IQ-AI Subsidiary’s Glioblastoma Therapy Obtains Fast-Track Designation From US FDA	20/12	MT
IQ-AI firm gets US FDA fast-track status for oral gallium maltolate	19/12	AN
IQ-AI's Imaging Biometrics Discloses Positive Results in Early-stage Study of Potential Brain Cancer Treatment	05/12	MT
IQ-AI stock rises on positive interim results from glioblastoma trial	05/12	AN
IQ-AI Unit Seeks Pediatric Rare Disease Designation for Brain Tumor Treatment	08/11	MT
IQ-AI says Imaging Biometrics submits paediatric rare disease request	08/11	AN
IQ-AI Applies for FDA Pediatric Rare Disease Designation	08/11	CI
IQ-AI subsidiary "central" to "landmark" brain cancer study	18/23/18	AN
IQ-AI subsidiary wins orphan drug designation from US FDA	09/23/09	AN
IQ-AI's Atypical Teratoid Rhabdoid Tumor Treatment Gains US FDA Orphan Drug Designation	09/23/09	MT
IQ-AI Halts Trading on OTCQB Venture Market in US; London Shares Up 13%	19/23/19	MT

Chart IQ-AI Limited

Duration

Period

More charts

Company Profile

IQ-AI Limited is a Jersey-based company, which is engaged in the provision of clinical treatments to patients in the field of medical imaging diagnostics, based on technology. The Company operates through two segments: holding company expenses and medical software. Its subsidiaries include Imaging Biometrics, LLC and Stone Checker Software Limited. Imaging Biometrics, LLC is a healthcare imaging software company. In addition to providing regulatory consulting services, Imaging Biometrics, LLC supplies medical technology solutions and has a neuroimaging product portfolio. Stone Checker Software Limited is a supplier of technology solutions in the field of kidney stone analysis and kidney stone prevention.

Sector

Healthcare Facilities & Services

Calendar

29/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
IQ-AI LIMITED	-68.09%	37.93L
SONIC HEALTHCARE LIMITED	-16.99%	867.4Cr
RADNET, INC.	+65.60%	425.4Cr
SYNLAB AG	-9.81%	247.01Cr
DR. LAL PATHLABS LIMITED	-1.19%	250.87Cr
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-44.11%	225.14Cr
NEOGENOMICS, INC.	-7.42%	191.44Cr
FLEURY S.A.	-18.68%	155.97Cr
DIAN DIAGNOSTICS GROUP CO.,LTD.	-41.75%	119.01Cr
METROPOLIS HEALTHCARE LIMITED	+11.31%	114.62Cr

Medical & Diagnostic Laboratories